Antibody molecules, or “immunoglobulins”, have been recognized only in vertebrates and all are found to have a fundamentally similar structure consisting of two heavy and two light peptide chains.

Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.